Craig Ornstein, PhD, MA

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs

Clinical Pathways GPS

Oncolytic Biosimilars: An Opportunity to Reduce Oncology Treatment Costs

04/21/2020

Craig Ornstein , PhD, MA;

Jamey Hardesty , MPH;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Matthew Pakizegee , PharmD, MS;

Uttama Rath , PhD, MS;

Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...

Inclusion of oncology biosimilars in clinical pathways is one approach to reducing costs in this therapeutic area without compromising outcomes for cancer patients. There are currently eight Food and Drug...

...

04/21/2020

Journal of Clinical Pathways

Perspectives

Approaching Clinical Pathway Development as an Art

11/18/2020

Craig Ornstein , PhD, MA;

Seth Gordon , MBA;

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Abstract: In health care, rules and regulations are in place for good reason, but there is an art to integrating them into care effectively to benefit patients as well as the other stakeholders—clinically and...

Abstract: In health care, rules and regulations are in place for good reason, but there is an art to integrating them into care effectively to benefit patients as well as the other stakeholders—clinically and...

...

11/18/2020

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

April 30 ⁠–⁠ May 5

WoundCon

May 1 ⁠–⁠ May 3

May 19 ⁠–⁠ May 21

See Full Calendar